YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

In the third quarter, Ascendis Pharma's growth hormone therapy Skytrofa is projected to possibly fall short of consensus revenue estimates of €61 million, with the firm's own forecast being € ...

Ascendis claims its drug delivery technology can be tailored to reduce dosing frequency or deliver a therapeutic molecule ...

The discount rate applied to these earnings remains unchanged at 10%. In the third quarter, Ascendis Pharma's growth hormone therapy Skytrofa is projected to possibly fall short of consensus revenue ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

The technology already has clinical and regulatory validation through two FDA-approved Ascendis products. Skytrofa, a drug for pediatric growth hormone deficiency, won its FDA nod in 2021.

The firm continues to like the Ascendis story heading into the U.S ... However, it trimmed its Q4 and Q4 Skytrofa revenue estimates and now models total 2024 Skytrofa revenue of EUR 215M.